Please provide your email address to receive an email when new articles are posted on . Post-treatment surveillance with bioimpedance spectroscopy — which uses an electric current to measure ...

This evolution is transforming bioimpedance spectroscopy into a mainstream health monitoring technology, bridging clinical precision with consumer accessibility. NEWARK, DE / ACCESS Newswire / April ...

BRISBANE, Australia & CARLSBAD, Calif.--(BUSINESS WIRE)--Publication of a new study to assess the validity of L-Dex bioimpedance spectroscopy (BIS) measurements for evaluating the effectiveness of ...

The increasing role of breast cancer lymphedema screening, diagnosis, and management as part of evidence-based breast cancer survivorship. This is an ASCO Meeting Abstract from the 2016 Cancer ...

ImpediMed Limited (ASX: IPD) has released a comprehensive business update from its Chief Executive Officer and Managing ...

Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim for the prevention of severe neutropenia, in patients with breast cancer receiving ...

The Food and Drug Administration granted breakthrough device designation to Impedimed’s Sozo device for kidney failure. The company’s bioimpedance spectroscopy device uses a mild electrical current to ...

PERTH, Australia – Impedimed Ltd.’s L-Dex bioimpedance technology could quickly become the standard of care for measuring cancer-related lymphedema following clinical trial results that showed a 59% ...

Bioimpedance spectroscopy (BIS) is better than a tape measure for assessing a woman's risk for developing lymphedema, painful swelling in the arm after breast cancer surgery, according to interim ...